ReviewJournal of cancer research and clinical oncology2023
Cancer-associated inflammation: pathophysiology and clinical significance.
Review in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of platelet to lymphocyte ratio in patients with castration-resistant prostate cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Prognostic value of nutritional and inflammatory biomarkers in patients with non-small cell lung cancer and bone metastasis: A retrospective study.Oncology letters · 2026Article
- Article
- Elevated baseline C-reactive protein predicts poorer survival in lung cancer: a 22-year retrospective cohort study.Translational lung cancer research · 2026Article
- Comparison of pre-treatment systemic inflammation indices (systemic immune-inflammation index, systemic inflammation response index, and inflammatory benchmark index) in predicting mortality risk in patients with pancreatic cancer.Contemporary oncology (Poznan, Poland) · 2026Article
- Targeting cancer hallmarks with microbiome-derived bacteriocins and postbiotics: molecular mechanisms and translational opportunities in oncology.Frontiers in oncology · 2026Review
- Predictive value of systemic inflammatory response index for the occurrence and prognosis of lung metastases in papillary thyroid carcinoma.American journal of translational research · 2026Article
- Cervicovaginal microbiome alterations across HPV infection.Frontiers in cellular and infection microbiology · 2026Article
- Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management.Journal of thrombosis and thrombolysis · 2025Review
- Review
- Fruit and Vegetable Intake in Relation to Lung Cancer Risk: A Systematic Review and Dose-response Meta-analysis of Prospective Cohort Studies.Journal of cancer prevention · 2025Review
- Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches.Journal of translational medicine · 2025Review
- Evaluating the Inflammatory Protein Ratio (IPR) as an Inflammation-Based Biomarker for Cancer Diagnosis.International journal of molecular sciences · 2025Article
- Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer-Where Are We Now?Cancers · 2025Review
- Preoperative neutrophil-to-lymphocyte ratio (NLR) value as a predictor of recurrence of non-muscle-invasive bladder cancer.International urology and nephrology · 2025Article
- Effect of Hemoglobin, Albumin, Lymphocyte Count, and Platelet (HALP) Score on Survival of Patients with Metastatic Thyroid Cancer Treated with Tyrosine Kinase Inhibitors.Journal of clinical medicine · 2025Article
- Identification of inflammation-related genes signature to establish a prognostic model in MGMT unmethylated glioblastoma patients.Discover oncology · 2025Article
- Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer cells, despite stemming from the own cells of their host, usually elicit an immune response. This response usually enables elimination of cancer at its earliest stages. However, some tumors develop mechanisms of escaping immune destruction and even profiting from tumor-derived inflammation.
methodsWe summarized the roles of different immune cell populations in various processes associated with cancer progression and possible methods of reshaping tumor-associated inflammation to increase the efficacy of cancer therapy.
resultsChanges in various signaling pathways result in attraction of immunosuppressive, pro-tumorigenic cells, such as myeloid-derived suppressor cells, tumor-associated macrophages, and neutrophils, while at the same time suppressing the activity of lymphocytes, which have the potential of destroying cancer cells. These changes promote tumor progression by increasing angiogenesis and growth, accelerating metastasis, and impairing drug delivery to the tumor site.
conclusionDue to its multi-faceted role in cancer, tumor-associated inflammation can serve as a valuable therapy target. By increasing it, whether through decreasing overall immunosuppression with immune checkpoint inhibitor therapy or through more specific methods, such as cancer vaccines, oncolytic viruses, or chimeric antigen receptor T cells, cancer-derived immunosuppression can be overcome, resulting in immune system destroying cancer cells. Even changes occurring in the microbiota can influence the shape of antitumor response, which could provide new attractive diagnostic or therapeutic methods. Interestingly, also decreasing the distorted tumor-associated inflammation with non-steroidal anti-inflammatory drugs can lead to positive outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.